## NLRP3 agonist 1

Cat. No.:	HY-156413				
CAS No.:	2454019-69-1				
Molecular Formula:	C <sub>15</sub> H <sub>16</sub> N <sub>6</sub>				
Molecular Weight:	280.33				
Target:	NOD-like Receptor (NLR)				
Pathway:	Immunology/Inflammation				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	6 months		
		-20°C	1 month		

## SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (356.72 mM; ultrasonic and warming and heat to 80°C)						
		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	3.5672 mL	17.8361 mL	35.6722 mL		
		5 mM	0.7134 mL	3.5672 mL	7.1344 mL		
		10 mM	0.3567 mL	1.7836 mL	3.5672 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (8.92 mM); Clear solution; Need ultrasonic						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (8.92 mM); Clear solution; Need ultrasonic						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (8.92 mM); Clear solution; Need ultrasonic						

OGICAL ACTIVIT
Description

## REFERENCES

HN-N

.NH<sub>2</sub>

Ν

ŃН

Ň



[1]. O' Donovan DH, et, al. Discovery and characterisation of quinazolines and 8-Azaquinazolines as NLRP3 agonists with oral bioavailability in mice. Bioorg Med Chem Lett. 2023 Oct 12:96:129518.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA